Provider review
yourEra review: a member-results figure with no count, no time frame and a 100% success rate
yourEra's homepage now leads with an outcome: members lose 13.6% of body weight on average, 84% reach 5%, and "100% lost weight". The first number sits inside what the trials found. The last needs a clear denominator and follow-up definition, and the figure comes with no member count, no time frame and no method beyond "self-reported data". Against that, yourEra now names the medical practice that prescribes and all three pharmacies that may fill the order, which most sellers never do. Prices start at $79 a month for semaglutide and $159 for tirzepatide; the refill interval behind those figures is shown only at checkout.
Partner link — we may earn a commission. How we’re paid
Visit yourEraOf yourEra’s 3 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Names its prescribers and all three pharmacies, which few sellers do, then leads with a member-results figure that has no count, no time frame and a 100% success rate.
Worth trusting if
- You want to know which medical practice prescribes and which pharmacies may fill your order before you sign up
- You want a written charging and cancellation process: charged only if prescribed, cancel from your account, full refund before dispatch
- You want the same price at every dose rather than a price that climbs as you titrate
Be skeptical if
- You want an outcome figure you can check, with a member count and a time frame
- You are buying the microdosing product and want to know which drug is in it
- You want to see the refill interval and refill price before you hand over card details
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Named
None found
Provenance
Products reviewed at yourEra
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Listed from $79 a month on the homepage, with "Same price at every dose". The refill interval and the price of each refill are shown at checkout.
- Compounded tirzepatide injection — Listed from $159 a month on the homepage, on the same "Same price at every dose" basis; the refill interval is shown at checkout.
- Microdosing Protocols — Listed from $179 a month, the dearest of yourEra's four priced products.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not yourEra's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from yourEra’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“-13.6% average body weight loss among YourEra members, roughly 29 lbs each. 84% reached the clinically meaningful 5% threshold and 100% lost weight.* […] *Based on YourEra member outcomes data. Individual results vary and are not guaranteed. […] Compounded Semaglutide: Weekly GLP-1 therapy that quiets food noise and supports lasting weight loss.”
Read on the yourEra site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg, mean weight reduction of about 15%. Most participants reached a 5% loss; not every participant lost weight, even at the full dose and with a full year and a half of treatment.
A selected reporting group can produce a 100% response figure; the missing denominator and follow-up prevent generalizing it to all starters. A 13.6% average loss sits a little under the roughly 15% STEP 1 reported at 68 weeks, and 84% reaching 5% is in the same range. "100% lost weight" does not establish a universal outcome: differences from a randomized trial do not make a member result impossible, but selection and missing follow-up can affect it. yourEra gives no member count, no time on treatment, no split by drug and no method beyond "self-reported data", so a reader cannot tell whether the 13.6% comes from a few dozen enthusiasts or thousands of patients at a year. Presented this way, the figure promises more certainty than it can carry.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Compounded Tirzepatide: Dual GIP/GLP-1 therapy, the next-generation approach to metabolic health. […] Tirzepatide activates two metabolic pathways at once, GIP and GLP-1, regulating appetite, blood sugar, and how your body stores energy. It's the choice for members who want the most advanced option, or who plateaued on single-pathway therapy.”
Read on the yourEra site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 21% at the top dose.
The tirzepatide copy stays on the mechanism and gets it right: a dual GIP and GLP-1 agent acting on appetite and blood sugar, which is what SURMOUNT-1 tested at up to 15 mg. "The most advanced option" is marketing rather than a finding, and the suggestion that it suits people who plateaued on semaglutide is a reasonable clinical idea that SURMOUNT-1 did not itself test, since it enrolled people who were not on a GLP-1. Nothing here puts a number on an outcome, and the site-wide member figure is graded on the semaglutide row.2
Microdosing ProtocolsGLP-1 microdose (molecule not named) · Compounded (503A)No trial supports this claim
“Microdosing Protocols: Structured low-dose protocols for mood, focus, and momentum. Never DIY. […] Sub-therapeutic dosing schedules paired with intention-setting, structured tracking, and monthly clinical review: evidence-informed support for mood, creativity, and cognitive momentum, with a licensed clinician at every step. […] from $179/mo”
Read on the yourEra site, September 2026
No trial for this use
No trial can be matched to this product because yourEra never says what is in it. Read on its own site in September 2026, the product panel describes sub-therapeutic dosing schedules for mood, focus and creativity and names no molecule and no dose. A trial record cannot be attached to an unnamed drug, and guessing which one it is would be inventing the evidence base.
"Evidence-informed support for mood, creativity, and cognitive momentum" is a claim with no evidence named behind it and no drug named inside it. The product sits under yourEra's weight-loss catalog, yet its own panel sells it for mood and focus rather than weight. Neither major GLP-1 trial studied a deliberately sub-therapeutic schedule or measured mood or creativity; both titrated participants up to a maintenance dose and measured weight. The site does link a named physician's own article on microdosing GLP-1s, hosted off-site, which is more than most sellers offer and still not a description of what is being sold.
Dispensing chain
Who actually fills your prescription
- Diversified Pharmacy, Inc. (MediVera Compounding Pharmacy, LLC)
- Galleria Medical Pharmacy, LLC
- VitalRX, LLC (VialsRx)
Read the full account
yourEra's terms name all three pharmacies that may fill a prescription: "Diversified Pharmacy, Inc., doing business as MediVera Compounding Pharmacy, LLC; Galleria Medical Pharmacy, LLC; or VitalRX, LLC, doing business as VialsRx. Which one fills your order depends on what is prescribed and on the state you live in." They also name the prescribers: "Your care is provided by licensed clinicians at Thryv Telehealth by Lavin, P.C." That is more than most sellers publish. Two things are worth knowing alongside it. The terms say yourEra provides management and administrative services to both the medical practice and one of the pharmacies, Galleria Medical Pharmacy, so the platform, a prescriber and a filler are tied together commercially. And the list tells you the three candidates, not which one will fill your order.
Read on the yourEra site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. The quality signals are "U.S. Licensed Pharmacies", a 4.8-star rating, before-and-after photographs and member stories, now under the label "Individual results vary and are not guaranteed." What yourEra does give a reader is the names of the three pharmacies, so a patient knows whom to ask for a lot record. The compounded-drug disclosure is in the footer and the FAQ: compounded drugs "are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality."
Read on the yourEra site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
yourEra publishes no list of states. Its terms say only that you must "live in a state where we operate" and that it ships "to addresses in the states where we operate", and its microdosing and sermorelin panels add that availability depends on your state.
Read the full licensing claim
The company is named with its address: Your Era Management, L.L.C., 1331 Ochsner Blvd., Suite 200, Covington, Louisiana, with Louisiana governing law. Its terms state plainly that "YourEra does not provide medical care and does not practice medicine or pharmacy" and name the medical practice, Thryv Telehealth by Lavin, P.C. No individual clinician or license number is published.
Read on the yourEra site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Its terms name the prescribing practice, Thryv Telehealth by Lavin, P.C., and all three pharmacies that may fill an order.
- Its terms say your card is charged only if a clinician issues a prescription, and state plainly that this usually happens without a live conversation.
- Cancellation is online and immediate, and an order canceled before dispatch is refunded in full.
Show 4 more
- Prices are the same at every dose, per its own homepage.
- The tirzepatide copy describes the mechanism accurately and puts no number on it.
- It links a named physician's own writing rather than anonymous blog posts.
- No FDA warning letter.
- Its headline member figure has no member count, no time frame and no method beyond "self-reported data".
- "100% lost weight" cannot be generalized to every new patient without a defined cohort and follow-up.
- The refill interval and refill price appear only at checkout, after the intake.
Show 3 more
- The microdosing product names no molecule and no dose, is sold for mood and focus, and is the dearest of its four priced products.
- yourEra provides management services to one of the pharmacies that fills its orders, and the list does not say which of the three will fill yours.
- No trial is cited anywhere, so nothing connects its products to published evidence.
Verdict
The bottom line
yourEra now tells you more about who is behind the service than almost any seller in this category: the prescribing practice, all three pharmacies and a plain account of when you are charged. Its evidence has gone the other way. The homepage leads with a member average and a 100% success rate that come with no count, no time frame and no method. Treat the 13.6% as marketing, and ask for the refill price and interval before you finish the intake.
Opens yourEra's website. A link is not a recommendation to take anything.
Confirm the refill offer, not just the welcome price
The October 13 public page describes a welcome kit, dose management and care messaging for its weight-loss programs. Those inclusions are helpful, but they do not by themselves identify the first payment, refill interval or next charge. The displayed price remains a starting figure. 3
Ask for an itemized quote and renewal schedule for the exact prescribed product, including any dose-related changes. Verify whether optional nutrition or training services are included now or belong to a separate future membership. Published descriptions of support should not be read as response times we have measured.
Full analysis — 4 more sectionsThe number on the homepage · Who prescribes and who fills · What the price covers · The product it will not describe
The number on the homepage
yourEra's homepage leads with an outcome:
"-13.6% average body weight loss among YourEra members, roughly 29 lbs each. 84% reached the clinically meaningful 5% threshold and 100% lost weight.*"
>
"*Based on YourEra member outcomes data. Individual results vary and are not guaranteed."
Two of those figures are in a believable range. STEP 1 reported a mean loss of about 15% at 68 weeks on semaglutide 2.4 mg, and most participants reached 5% 1. A member average a little under that is plausible.
"100% lost weight" is not. No controlled trial of semaglutide or tirzepatide reported every participant losing weight, even at full dose over more than a year 1 2. When a seller reports a perfect rate, the usual explanation is who is being counted: members who stayed on treatment and chose to report back.
yourEra gives nothing that would settle it. There is no member count, no time on treatment, no split between semaglutide and tirzepatide, and the only method stated is "self-reported data". The member stories below the figure, including "Down 42 lbs in 4 months" and "94 lbs lost", carry the label "Individual results vary and are not guaranteed."
Who prescribes and who fills
This is where yourEra is better than most. Its terms say:
"Your care is provided by licensed clinicians at Thryv Telehealth by Lavin, P.C."
"Your prescription is filled by one of three pharmacies: Diversified Pharmacy, Inc., doing business as MediVera Compounding Pharmacy, LLC; Galleria Medical Pharmacy, LLC; or VitalRX, LLC, doing business as VialsRx."
The same terms state that yourEra provides management and administrative services to the medical practice and to Galleria Medical Pharmacy. That is disclosed rather than hidden, and it is worth knowing: the platform, a prescriber and one of the fillers are tied together commercially.
The terms are also unusually plain about money. You authorize the charge when you submit the intake, you are charged only if a clinician prescribes, and "in most cases that means you will be charged without having spoken to a clinician first." Cancellation is from your account and takes effect immediately.
What the price covers
The catalog:
Semaglutide from $79/mo · Tirzepatide from $159/mo · NAD+ from $170/mo · Microdosing Protocols from $179/mo
The homepage adds "Same price at every dose. No hidden fees." What it does not show is how often you are billed or what each refill costs. The terms say those are "shown at checkout before you provide payment details", which is after the intake.
The product it will not describe
The microdosing product is the most expensive of the four priced products and the only one with no drug named. Its panel sells "sub-therapeutic dosing schedules" for "mood, creativity, and cognitive momentum", not weight.
Neither major trial studied that. Both titrated participants up to a maintenance dose and measured weight 1 2, so a deliberately reduced dose aimed at mood is a different treatment with its own, unstated, evidence base.
Questions
Frequently asked questions
Is the 13.6% average loss real?
It may be, but it can't be checked. yourEra gives no member count, no time on treatment and no method beyond self-reported data. A similar average to STEP 1 does not establish equivalent evidence. Without the denominator and follow-up method, a reader cannot distinguish a complete cohort from selected respondents, or generalize the 100% figure to new patients.
Is compounded GLP-1 really $79 a month?
That is where semaglutide starts on the homepage, with tirzepatide from $159. yourEra says the price is the same at every dose. How often you are billed and what each refill costs are shown at checkout, after the intake, so check both before you enter card details.
Who makes the medication?
One of three named pharmacies: MediVera Compounding Pharmacy, Galleria Medical Pharmacy or VialsRx. yourEra's terms say which one fills your order depends on what is prescribed and on your state. Prescriptions are written by clinicians at Thryv Telehealth by Lavin, P.C.
When is my card charged?
Only if a clinician issues a prescription. You authorize the charge when you submit the intake, and yourEra says plainly that in most cases the review happens without a live conversation. You can ask for a live visit at no extra charge, and an order canceled before it ships is refunded in full.
What is the microdosing protocol?
yourEra doesn't say which drug it is. Its panel describes low-dose schedules for mood, focus and creativity, with no molecule and no dose, and it is the dearest of the four priced products. Neither major GLP-1 trial studied a deliberately low dose or measured mood.
Glossary
Key terms
Show definitions
- Titration
- Starting at a low dose and stepping up over weeks to a target. Both major weight-loss trials titrated participants up and measured results at the maintenance dose, which is why results from a deliberately lower dose are not covered by them.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
Compare
Others selling what yourEra sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists yourEra is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off yourEra's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, titrated to a 2.4 mg maintenance dose. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the yourEra site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.